University of Washington
This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
OUTLINE: Patients receive mosunetuzumab intravenously (IV) over 2-4 hours on days 1, 8, 15 and 22. Patients also undergo blood sample collection and positron emission tomography (PET)/computed tomography (CT) on study. Patients may undergo CT and/or magnetic resonance imaging (MRI) as clinically indicated and may undergo collection of oral and/or rectal swabs on study. After completion of study treatment, patients are followed up at week 13, at 6 months, and then for up to 5 years per institutional standards.
Inclusion Criteria: * 18 years or older at time of signing informed consent * Capable of understanding and providing written informed consent * Histologically confirmed indolent B-cell non-Hodgkin lymphoma with no prior therapy for lymphoma. (Prior peptide-based therapeutic vaccines are allowed.) Eligible histologies include: * Follicular lymphoma (grade 1-2 or 3A) * Marginal zone lymphoma * Ann Arbor stage II-IV disease * No prior therapy for lymphoma * Have low-tumor burden disease, defined by Groupe D'Etude des Lymphomes Folliculaires (GELF) criteria: * Nodal or extranodal tumor ma…
Undergo blood, oral, and/or rectal sample collection
Undergo PET/CT or CT
Undergo MRI
Given IV
Undergo PET/CT
Ancillary studies
Arctuva estimate
Verify or correct the compensation shown for this listing.